Vincerx Pharma, Inc. Quarterly Debt-to-equity in % from Q3 2020 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Vincerx Pharma, Inc. quarterly Debt-to-equity history and growth rate from Q3 2020 to Q3 2024.
  • Vincerx Pharma, Inc. Debt-to-equity for the quarter ending September 30, 2024 was 87.1 %, a 130% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 87.1 +49.2 +130% Sep 30, 2024
Q2 2024 84.5 +55.3 +190% Jun 30, 2024
Q1 2024 80 +56.6 +241% Mar 31, 2024
Q4 2023 48.7 +29.3 +152% Dec 31, 2023
Q3 2023 37.9 +20 +111% Sep 30, 2023
Q2 2023 29.2 +8.8 +43.2% Jun 30, 2023
Q1 2023 23.4 +1.2 +5.4% Mar 31, 2023
Q4 2022 19.3 -13.6 -41.3% Dec 31, 2022
Q3 2022 18 -35.2 -66.2% Sep 30, 2022
Q2 2022 20.4 -56.2 -73.4% Jun 30, 2022
Q1 2022 22.2 -131 -85.5% Mar 31, 2022
Q4 2021 32.9 -161 -83% Dec 31, 2021
Q3 2021 53.2 +1.94K Sep 30, 2021
Q2 2021 76.6 Jun 30, 2021
Q1 2021 153 Mar 31, 2021
Q4 2020 194 Dec 31, 2020
Q3 2020 -1.89K Sep 30, 2020
* An asterisk sign (*) next to the value indicates that the value is likely invalid.